Startup Trends: Companies to achieve notable funding rounds in Q1 2024
Five companies – Lambda, Alumis, Freenome, Applied Intuition, and Glean – celebrated notable funding hauls in the past quarter.
freenome.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $2.46B
Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/15/2024 | Series F | $254MM | $xx.xx | $2.17B | Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital Life Sciences, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
34,330,819
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital Life Sciences, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
|
||||||
01/11/2022 | Series E | $290MM | $xx.xx | $2.74B | Roche | |
Price per Share
$xx.xx
Shares Outstanding
24,856,432
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Roche
|
||||||
12/07/2021 | Series D | $300MM | $xx.xx | $1.43B | Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
39,775,664
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, T. Rowe Price Associates
|
||||||
08/26/2020 | Series C | $270MM | $xx.xx | $927.08MM | American Cancer Society�S Brightedge Ventures, Andreessen Horowitz, Bain Capital, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv (Formerly Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
40,826,799
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
American Cancer Society�S Brightedge Ventures, Andreessen Horowitz, Bain Capital, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv (Formerly Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
|
||||||
07/24/2019 | Series B | $165MM | $xx.xx | $464.3MM | Andreessen Horowitz, Brightedge Ventures, Data Collective Venture Capital, Gv, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Section 32, T. Rowe Price Associates, Verily Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
36,207,457
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Brightedge Ventures, Data Collective Venture Capital, Gv, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Section 32, T. Rowe Price Associates, Verily Life Sciences
|
||||||
08/28/2017 | Series A | $69.62MM | $xx.xx | $196.16MM | Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28 | |
Price per Share
$xx.xx
Shares Outstanding
22,660,320
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
|
||||||
06/19/2016 | Series Seed-2 | $5.55MM | $xx.xx | $25.34MM | Andreessen Horowitz, Data Collective, Founders Fund, Third Kind Venture Capital | |
Price per Share
$xx.xx
Shares Outstanding
9,092,395
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Data Collective, Founders Fund, Third Kind Venture Capital
|
||||||
05/06/2016 | Series Seed-1 | $800,016.00 | $xx.xx | $2.67MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,360,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
Five companies – Lambda, Alumis, Freenome, Applied Intuition, and Glean – celebrated notable funding hauls in the past quarter.